Treating prostate cancer: A rationale for targeting local oestrogens

Stuart John Ellem, Gail Petuna Risbridger

    Research output: Contribution to journalArticleResearchpeer-review

    98 Citations (Scopus)


    Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer-related death in men, and benign prostatic hyperplasia is the most common benign condition known to occur in ageing men. Oestrogen has been implicated in the development of prostate cancer, and offers a promising new avenue for treatment. Despite this, the role of oestrogens in the prostate is complex. This Perspective presents a rationale for a targeted approach for the treatment of prostate disease through the use of selective oestrogen-receptor modulators in conjunction with contemporary androgen-ablation therapy.
    Original languageEnglish
    Pages (from-to)621 - 627
    Number of pages7
    JournalNature Reviews Cancer
    Issue number8
    Publication statusPublished - 2007

    Cite this